ReachRxResearch
Home
Research
Sign Up
  1. Home
  2. Research Hub
  3. Progress report on new epilepsy treatmen…

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices ( EILAT XVIII ). I. Treatments in preclinical and early clinical development

Epilepsia·July 18Open Access
Clinical NeurologyLimited evidenceEpilepsyFocal Cortical DysplasiaFocal SeizuresLafora DiseaseMesial Temporal Lobe EpilepsyTuberous Sclerosis ComplexConference Proceedings / Narrative ReviewAntisense OligonucleotideFilamin A ModulatorGABA Aminotransferase InhibitorMEK InhibitorPannexin 1 Channel BlockerPhosphodiesterase 4B InhibitorPotassium Channel ModulatorTau Dephosphorylation PromoterMixedPTI5803AUT00206ION283MSCA-7136OV329ProbenecidSimufilamSN-2000Sodium Selenate

Summary

View source

What was studied

This conference report summarizes eight investigational treatments for epilepsy — in preclinical and early clinical development — presented at the EILAT XVIII conference (Madrid, May 2026), covering novel mechanisms including potassium channel modulation, antisense oligonucleotides, MEK inhibition, GABA aminotransferase inhibition, pannexin 1 blockade, filamin A modulation, PDE4B inhibition, and tau dephosphorylation promotion.

Key findings

Eight agents were reviewed: AUT00206 (Kv3.1/3.2 PAM), ION283 (ASO for Lafora disease), MSCA-7136 (MEK inhibitor for focal/TSC seizures), OV329 (GABA aminotransferase inhibitor), PTI5803/probenecid (pannexin 1 blocker for focal cortical dysplasia), simufilam (filamin A modulator for TSC epilepsy), SN-2000 (PDE4B inhibitor for focal seizures), and sodium selenate (disease-modifying agent for mesial temporal lobe epilepsy); no clinical efficacy or safety outcome data are reported in the abstract.

Study limitations

Full text was inaccessible — only the abstract was available; no quantitative efficacy, safety, or tolerability data are presented; all agents are preclinical or in early clinical stages, limiting clinical applicability.

Clinical implications

These agents represent a diverse pipeline of novel mechanisms for drug-resistant and rare epilepsies, but none are yet ready for clinical use — clinicians should monitor their progression in future trials.

Related Questions

Explore related topics

What new antiepileptic drugs are in early clinical trials for drug-resistant focal seizures?What treatments are being developed for Lafora disease and other rare epilepsy syndromes?How does MEK inhibition work as a treatment for tuberous sclerosis complex-related seizures?

Publication Details

Year
2026
Journal
Epilepsia
Source
View article
Keep scrolling
More content below.
Up Next